198 related articles for article (PubMed ID: 27094504)
21. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
[TBL] [Abstract][Full Text] [Related]
22. Honokiol induces cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia.
Ishikawa C; Arbiser JL; Mori N
Biochim Biophys Acta; 2012 Jul; 1820(7):879-87. PubMed ID: 22465179
[TBL] [Abstract][Full Text] [Related]
23. PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone.
Zhao H; Gu H; Zhang H; Li JH; Zhao WE
Biochim Biophys Acta; 2014 Jan; 1840(1):545-55. PubMed ID: 24036327
[TBL] [Abstract][Full Text] [Related]
24. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
[TBL] [Abstract][Full Text] [Related]
25. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
26. 4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity.
Lee NJ; Oh JH; Ban JO; Shim JH; Lee HP; Jung JK; Ahn BW; Yoon DY; Han SB; Ham YW; Hong JT
Br J Pharmacol; 2013 Mar; 168(5):1133-45. PubMed ID: 23043610
[TBL] [Abstract][Full Text] [Related]
27. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
Cheung KF; Zhao J; Hao Y; Li X; Lowe AW; Cheng AS; Sung JJ; Yu J
Cancer; 2013 Mar; 119(6):1217-26. PubMed ID: 23212831
[TBL] [Abstract][Full Text] [Related]
28. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Yuan Y; Zhang A; Huang S; Ding G; Chen R
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
[TBL] [Abstract][Full Text] [Related]
29. Anti-proliferative effect of rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells.
Wei R; Yu F; Yang J; Gao H; Wang H; Hong T
Cell Biol Int; 2018 May; 42(5):515-524. PubMed ID: 29274299
[TBL] [Abstract][Full Text] [Related]
30. Viscum Album Var Hot Water Extract Mediates Anti-cancer Effects through G1 Phase Cell Cycle Arrest in SK-Hep1 Human Hepatocarcinoma cells.
dela Cruz JF; Kim YS; Lumbera WM; Hwang SG
Asian Pac J Cancer Prev; 2015; 16(15):6417-21. PubMed ID: 26434853
[TBL] [Abstract][Full Text] [Related]
31. Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Cao LQ; Shao ZL; Peng HP; Xiao JB; Xia T
Chin J Cancer; 2010 Aug; 29(8):741-6. PubMed ID: 20663321
[TBL] [Abstract][Full Text] [Related]
32. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.
Singh T; Gupta NA; Xu S; Prasad R; Velu SE; Katiyar SK
Oncotarget; 2015 Aug; 6(25):21268-82. PubMed ID: 26020804
[TBL] [Abstract][Full Text] [Related]
33. [Honokiol-induced apoptosis of human non-Hodgkin lymphoma Raji cells and its possible mechanism].
Chen W; Lin GW; Zhang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1918-21. PubMed ID: 22126780
[TBL] [Abstract][Full Text] [Related]
34. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
35. Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.
Liu SH; Shen CC; Yi YC; Tsai JJ; Wang CC; Chueh JT; Lin KL; Lee TC; Pan HC; Sheu ML
Br J Pharmacol; 2010 Aug; 160(8):1963-72. PubMed ID: 20649594
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
37. Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells.
Lu CH; Chen SH; Chang YS; Liu YW; Wu JY; Lim YP; Yu HI; Lee YR
Pharmacol Res; 2017 Jan; 115():288-298. PubMed ID: 27940017
[TBL] [Abstract][Full Text] [Related]
38. Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
Cao LQ; Wang XL; Wang Q; Xue P; Jiao XY; Peng HP; Lu HW; Zheng Q; Chen XL; Huang XH; Fu XH; Chen JS
Acta Pharmacol Sin; 2009 Sep; 30(9):1316-22. PubMed ID: 19684609
[TBL] [Abstract][Full Text] [Related]
39. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.
Burrage PS; Schmucker AC; Ren Y; Sporn MB; Brinckerhoff CE
Arthritis Res Ther; 2008; 10(6):R139. PubMed ID: 19046432
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma.
Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH
Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
